ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
April 29, 2024 16:05 ET
|
ACELYRIN, INC.
LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative...
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
March 28, 2024 16:05 ET
|
ACELYRIN, INC.
Reported positive Phase 1/2 proof-of-concept data for lonigutamab, first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease patients Achieved primary endpoint with high...
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
March 20, 2024 07:00 ET
|
ACELYRIN, INC.
Rapid improvements demonstrated for proptosis, clinical activity scores, and diplopia versus placebo with a favorable safety profile Phase 2b/3 trial to be initiated in the second half of 2024 ...
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
March 11, 2024 08:02 ET
|
ACELYRIN, INC.
Study met primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance and is expected to be the first of two registrational trials in psoriatic arthritis Robust clinical...
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
March 11, 2024 08:00 ET
|
ACELYRIN, INC.
Dose ordered and robust HiSCRs were rapidly demonstrated with about a third of patients achieving HiSCR100, or resolution of abscesses and nodules, by week 16 and through week 32 Deep and...
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
February 15, 2024 16:05 ET
|
ACELYRIN, INC.
Highly accomplished leader bringing more than 25 years of investor relations, communications, and operational & strategic finance experience at public healthcare companies LOS ANGELES, Feb. 15,...
ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors
December 20, 2023 16:30 ET
|
ACELYRIN, INC.
Former Executive Vice President of Human Resources and Corporate Affairs at AstraZeneca PLC brings more than 30 years of strategic expertise in human resources, business operations, and corporate...
ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
November 27, 2023 16:30 ET
|
ACELYRIN, INC.
LOS ANGELES, Nov. 27, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines...
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
November 07, 2023 16:05 ET
|
ACELYRIN, INC.
Portfolio of programs continues to advance with data from both the global Phase 2b/3 trial for izokibep in PsA and proof-of-concept for lonigutamab as a subcutaneous treatment for thyroid eye disease...
ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer
November 06, 2023 07:00 ET
|
Acelyrin, Inc.
Expands capacity for multi-asset manufacturing with highly accomplished supply chain, manufacturing and quality control leader bringing more than 25 years of biopharmaceutical experience across...